参考文献
[1]
EthunCG, Lopez-AguiarAG, PawlikTM, et al.
Distal cholangiocarcinoma and pancreas adenocarcinoma: Are they really the same disease A 13-institution study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium[J].
J Am Coll Surg,
2017,
224(
4):
406-
413.
.
[2]
HoyosS, NavasMC, RestrepoJC, et al.
Current controversies in cholangiocarcinoma[J].
Biochim Biophys Acta,
2017
.
pii: S0925-4439(
17)
30259-
4.
.
[3]
HaradaK, ShimodaS, KimuraY, et al.
Significance of immunoglobulin G4 (IgG4)-positive cells in extrahepatic cholangiocarcinoma: molecular mechanism of IgG4 reaction in cancer tissue[J].
Hepatology,
2012,
56(
1)：
157-
164.
.
[4]
虞积耀，崔全才
.
世界卫生组织组织肿瘤分类及诊断标准系列：消化系统肿瘤病理学和遗传学[M]. 第
1版，
北京：
北京人民卫生出版社，
2006：
246-
262.
[5]
GrunnetM, Mau-SørensenM.
Serum tumor markers in bile duct cancer － a review[J].
Biomarkers，
2014，
19(
6)：
437-
443.
.
[6]
LiskaV, TreskaV, SkalickyT, et al.
Evaluation of tumor mar-kers and their impact on prognosis in gallbladder, bile duct and cholangiocellular carcinomas － a pilot study[J].
Anticancer Res,
2017,
37(
4):
2003-
2009.
.
[7]
AyusoJR, PagésM, DarnellA.
Imaging bile duct tumors: staging[J].
Abdom Imaging,
2013,
38(
5)：
1071-
1081.
.
[8]
MarWA, ShonAM, LuY, et al.
Imaging spectrum of cholangiocarcinoma: role in diagnosis, staging, and posttreatment evaluation[J].
Abdom Radiol (NY),
2016,
41(
3)：
553-
567.
.
[9]
ChenL, LuY, WuJC, et al.
Diagnostic utility of endoscopic re-trograde cholangiography/intraductal ultrasound (ERC/IDUS) in distinguishing malignant from benign bile duct obstruction[J].
Dig Dis Sci,
2016，
61(
2)：
610-
617.
.
[10]
ValleJW, BorbathI, KhanSA, et al.
ESMO Guidelines Committee. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J].
Ann Oncol,
2016，
27(
suppl 5)：
v28-
v37.
.
[11]
魏小丽，董卫国.
超声内镜对壶腹部周围病变的诊断价值研究[J].
临床消化病杂志，
2016，
28(
2)：
71-
75.
.
[12]
PitmanMB, LayfieldLJ.
Guidelines for pancreaticobiliary cytology from the Papanicolaou Society of Cytopathology: a review[J].
Cancer Cytopathol,
2014,
122(
6)：
399-
411.
.
[13]
汪丽菁，程向东，俞鹏飞，等.
造影增强超声内镜和增强CT对壶腹周围肿瘤可切除性评估的比较观察[J].
中华医学杂志，
2015，
95(
24)：
1921-
1924.
.
[14]
BlechaczB, KomutaM, RoskamsT, et al.
Clinical diagnosis and staging of cholangiocarcinoma[J].
Nat Rev Gastroenterol Hepatol,
2011，
8(
9)：
512-
522.
.
[15]
KippBR, StadheimLM, HallingSA, et al.
A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures[J].
Am J Gastroenterol,
2004，
99(
9)：
1675-
1681.
.
[16]
HallingKC, KippBR.
Fluorescence in situ hybridization in diagnostic cytology[J].
Hum Pathol,
2007,
38(
8):
1137-
1144.
.
[17]
Barr FritcherEG, VossJS, BrankleySM, et al.
An optimized set of fluorescence in situ hybridization probes for detection of pancreatobiliary tract cancer in cytology brush samples[J].
Gastroente-rology,
2015，
149(
7)：
1813-
1824.
.
[18]
SugiyamaH, TsuyuguchiT, SakaiY, et al.
Current status of preoperative drainage for distal biliary obstruction[J].
World J Hepatol,
2015，
7(
18)：
2171-
2176.
.
[19]
El NakeebA, SalemA, MahdyY, et al.
Value of preoperative biliary drainage on postoperative outcome after pancreaticoduodenectomy: a case-control study[J].
Asian J Surg,
2016
.
pii: S1015-9584(
16)
30240-
8.
.
[20]
MooleH, BechtoldM, PuliSR.
Efficacy of preoperative biliary drainage in malignant obstructive jaundice: a meta-analysis and systematic review[J].
World J Surg Oncol,
2016,
14(
1)：
182.
.
[21]
HuBing, ZhouDaiyun, GongBiao, et al.
Endoscopic palliative treatment for malignant obstructive jaundice: a report of 929 cases[J].
Chinese-Geman J Clin Oncol,
2002,
1(
1)：
32-
35.
[22]
SasahiraN, HamadaT, TogawaO, et al.
Multicenter study of endoscopic preoperative biliary drainage for malignant distal biliary obstruction[J].
World J Gastroenterol,
2016,
22(
14)：
3793-
3802.
.
[23]
BrierleyJames D., MaryK, G ospodarowicz, et al.
Union for International Cancer Control (UICC). TNM classification of malignant tumours (Eighth Edition)[M].
US:
John Wiley & Sons, Ltd.
2017：
89-
92.
[24]
孙立臣，张柏和，张永杰，等.
远端胆管癌预后因素分析[J].
中华外科杂志，
2004，
42(
9)：
528-
531.
[25]
ChengQ, LuoX, ZhangB, et al.
Distal bile duct carcinoma: prognostic factors after curative surgery. A series of 112 cases[J].
Ann Surg Oncol,
2007,
14(
3)：
1212-
1219.
.
[26]
郑树森，秦运升，梁廷波，等.
肝外胆管癌外科治疗的远期疗效评价[J].
中华肿瘤杂志，
2005，
27(
9)：
554-
556.
.
[27]
路夷平，陈雷，乔岐禄，等.
远端胆管癌切除患者术后生存的影响因素分析[J].
中华普通外科杂志，
2010，
25(
6)：
476-
479.
.
[28]
孙立臣，张柏和，姜小清，等.
远端胆管癌手术方式的选择[J].
中国实用外科杂志，
2005，
25(
2)：
89-
91.
.
[29]
IsoY, KitaJ, KatoM, et al.
When hepatic-side ductal margin is positive in N＋ cases, additional resection of the bile duct is not necessary to render the negative hepatic-side ductal margin during surgery for extrahepaticdistal bile duct carcinoma[J].
Med Sci Monit,
2014，
20：
471-
475.
.
[30]
RoderJD, SteinHJ, SiewertJR.
Carcinoma of the periampullary region: who benefits from portal vein resection [J].
Am J Surg，
1996，
171(
1)：
170-
174.
.
[31]
KurosakiI, HatakeyamaK, MinagawaM, et al.
Portal vein resection in surgery for cancer of biliary tract and pancreas: special reference to the relationship between the surgical outcome and site of primary tumor[J].
J Gastrointest Surg,
2008，
12(
5)：
907-
918.
.
[32]
BahraM, JacobD, LangrehrJM, et al.
Carcinoma of the distal and middle bile duct: surgical results, prognostic factors, and long-term follow-up[J].
J Hepatobiliary Pancreat Surg,
2008,
15(
5)：
501-
507.
.
[33]
MiuraF, SanoK, AmanoH, et al.
Evaluation of portal vein invasion of distal cholangiocarcinoma as borderline resectability[J].
J Hepatobiliary Pancreat Sci,
2015，
22(
4)：
294-
300.
.
[34]
别平，丁钧，范毓东，等.
门静脉主干低温灌注下切除侵犯门静脉的胰头癌及胆管癌[J].
中华消化外科杂志，
2007，
6(
2)：
140-
141.
.
[35]
梁建伟，赵平，周志祥，等.
中下段胆管癌切除后切缘阳性的意义及预后因素分析[J].
中华外科杂志，
2009，
47(
9)：
677-
680.
.
[36]
AhnKS, KangKJ, KangYN, et al.
Confinement to the intrapancreatic bile duct is independently associated with a better prognosis in extrahepatic cholangiocarcinoma[J].
BMC Gastroenterol,
2016，
16：
21.
.
[37]
MiyazakiM, OhtsukaM, MiyakawaS, et al.
Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3(rd) English edition[J].
J Hepatobiliary Pancreat Sci,
2015，
22(
3)：
181-
196.
.
[38]
NojiT, MiyamotoM, KubotaKC, et al.
Evaluation of extra capsular lymph node involvement in patients with extra-hepatic bile ductcancer[J].
World J Surg Oncol,
2012，
10：
106.
.
[39]
GutierrezJC, FranceschiD, KoniarisLG.
How many lymph nodes properly stage a periampullary malignancy [J].
J Gastrointest Surg,
2008，
12(
1)：
77-
85.
.
[40]
PomianowskaE, WestgaardA, MathisenØ，et al.
Prognostic relevance of number and ratio of metastatic lymph nodes in resected pancreatic, ampullary, and distal bile duct carcinomas[J].
Ann Surg Oncol,
2013，
20(
1)：
233-
241.
.
[41]
MoonA, ChoiDW, ChoiSH, et al.
Validation of T stage accor-ding to depth of invasion and N stage subclassification based on number of metastatic lymph nodes for distal extrahepatic bile duct (EBD) carcinoma[J].
Medicine (Baltimore),
2015,
94(
50)：
e2064.
.
[42]
KimHJ, KimCY, HurYH, et al.
The prognostic factors for survival after curative resection of distal cholangiocarcinoma: perineural invasion and lymphovascular invasion[J].
Surg Today,
2014,
44(
10)：
1879-
186.
.
[43]
EthunCG, Lopez-AguiarAG, PawlikTM, et al.
Distal cholangiocarcinoma and pancreas adenocarcinoma: Are they really the same disease A 13-institution study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium[J].
J Am Coll Surg,
2017,
224(
4)：
406-
413.
.
[44]
KomayaK, EbataT, ShiraiK, et al.
Nagoya Surgical Oncology Group. Recurrence after resection with curative intent for distal cholangiocarcinoma[J].
Br J Surg,
2017,
104(
4)：
426-
433.
.
[45]
ErcolaniG, DazziA, GiovinazzoF, et al.
Intrahepatic, peri-hilar and distal cholangiocarcinoma: Three different locations of the same tumor or three different tumors [J].
Eur J Surg Oncol,
2015,
41(
9)：
1162-
1169.
.
[46]
EbataT, NaginoM, NishioH, et al.
Pancreatic and duodenal invasion in distal bile duct cancer: paradox in the tumor classification of the American Joint Committee on Cancer[J].
World J Surg,
2007,
31(
10)：
2008-
2015.
.
[47]
詹茜，沈柏用，邓侠兴，等.
手术切除联合化疗对胆管癌患者生存率的影响：242例病例的多变量分析[J].
上海医学，
2011,
34(
11)：
828-
830.
[48]
ErdmannJI, MorakMJ, DuivenvoordenHJ, et al.
Long-term survival after resection for non-pancreatic periampullary cancer followed by adjuvantintra-arterial chemotherapy and concomitant radiotherapy[J].
HPB (Oxford).
2015；
17(
7)：
573-
9.
.
[49]
WangY, DuanB, YanL, et al.
Long-term outcome after surgical resection for cholangiocarcinoma and prognostic index value[J].
Surgeon,
2016,
14(
1)：
38-
43.
.
[50]
KimYS, HwangIG, ParkSE, et al.
Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma[J].
Cancer Chemother Pharmacol,
2016，
77(
5):
979-
985.
.
[51]
ValleJ, WasanH, PalmerDH, et al.
ABC-02 Trial Investigators.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J].
N Engl J Med,
2010，
362(
14)：
1273-
1281.
.
[52]
OkusakaT, NakachiK, FukutomiA, et al.
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan[J].
Br J Cancer,
2010，
103(
4)：
469-
474.
.
[53]
ValleJW, FuruseJ, JitlalM, et al.
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials[J].
Ann Oncol,
2014，
25(
2)：
391-
398.
.
[54]
SteinA, ArnoldD, BridgewaterJ, et al.
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary，multinational phase III trial[J].
BMC Cancer,
2015，
15：
564.
.
[55]
MoriwakiT, YamamotoY, GoshoM, et al.
Correlations of survi-val with progression-free survival, response rate, and disease control rate inadvanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy[J].
Br J Cancer,
2016，
114(
8):
881-
888.
.
[56]
MorizaneC, OkusakaT, MizusawaJ, et al.
Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial [J].
Cancer Science，
2013，
104(
9)：
1211-
1216.
.
[57]
KimHS, KimHY, ZangDY, et al.
Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastaticbiliary tract cancer[J].
Cancer Chemother Pharmacol，
2015，
75(
4)：
711-
718.
.
[58]
MizusawaJ, MorizaneC, OkusakaT, et cl;
Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group.
Randomized phase III study of gemcitabine plus S-1 versus gemci-tabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)[J].
Jpn J Clin Oncol,
2016，
46(
4)：
385-
388.
.
[59]
ArimaS, ShimizuK, OkamotoT, et al.
A multicenter phase II study of gemcitabine plus S-1 chemotherapy for advanced biliary tract cancer[J].
Anticancer Res,
2017，
37(
2)：
909-
914.
.
[60]
LeeDW, ImSA, KimYJ, et al.
CA19-9 or CEA decline after the first cycle of treatment predicts survival in advanced biliary tract cancer patients treated with S-1 and cisplatin chemotherapy[J].
Cancer Res Treat,
2017，
49(
3)：
807-
815.
.
[61]
FornaroL, VivaldiC, CeredaS, et al.
On behalf of the GICO group (Gruppo Italiano COlangiocarcinoma). Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data[J].
J Exp Clin Cancer Res,
2015,
34:
156.
.
[62]
AraiY, TotokiY, HosodaF, et al.
Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma[J].
Hepatology,
2014,
59(
4)：
1427-
1434.
.
[63]
JavleMM, ShroffRT, ZhuA, et al.
A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy[J].
J Clin Oncol,
2016,
34 (
4_
suppl):
335.
.
[64]
FarshidfarF, ZhengS, GingrasMC, et al.
Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-Mutant Molecular Profiles[J].
Cell Rep,
2017,
18(
11)：
2780-
2794.
.
[65]
AndersenJB, SpeeB, BlechaczBR, et al.
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors[J].
Gastroenterology,
2012，
142(
4)：
1021-
1031.
.
[66]
TakahashiH, OjimaH, ShimizuH, et al.
Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma[J].
Jpn J Clin Oncol,
2014,
44(
6)：
570-
578.
.
[67]
LeeJ, ParkSH, ChangHM, et al.
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study[J].
Lancet Oncol,
2012,
13(
2)：
181-
188.
.
[68]
ValleJW, LamarcaA, GoyalL, et al.
New horizons for precision medicine in biliary tract cancers[J].
Cancer Discov,
2017,
7(
9)：
943-
962.
.
[69]
JusakulA, CutcutacheI, YongCH, et al.
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma[J].
2017
.
.
[70]
KhanSA, ThomasHC, ToledanoMB, et al.
p53 Mutations in human cholangiocarcinoma: a review[J].
Liver Int,
2005,
25(
4)：
704-
716.
.
[71]
SatoY, KinoshitaM, TakemuraS, et al.
The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma[J].
Pathol Int,
2017，
67(
3)：
163-
170.
.
[72]
KooTR, EomKY, KimIA, et al.
Patterns of failure and prognostic factors in resected extrahepatic bile duct cancer: implication for adjuvant radiotherapy[J].
Radiat Oncol J,
2014，
32(
2)：
63-
69.
.
[73]
Ben-JosefE, GuthrieKA, El-KhoueiryAB, et al.
SWOG S0809: A phase II intergroup trial of adjuvant capecitabine and gemci-tabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J].
J Clin Oncol,
2015，
33(
24)：
2617-
2622.
.
[74]
AutorinoR, MattiucciGC, ArditoF, et al.
Radiochemotherapy with gemcitabine in unresectable extrahepatic cholangiocarcinoma: long-term results of a phase II study[J].
Anticancer Res,
2016，
36(
2)：
737-
740.
[75]
ShinHS, SeongJ, KimWC, et al.
Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for ino-perable carcinoma of the extrahepatic bile ducts[J].
Int J Radiat Oncol Biol Phys,
2003，
57(
1)：
105-
112.
[76]
SaitoH, TakadaT, MiyazakiM, et al.
Japanese Association of Biliary Surgery; Japanese Society of Hepato-Biliary-Pancreatic Surgery; Japan Society of Clinical Oncology. Radiation therapy and photodynamic therapy for biliary tract and ampullary carcinomas[J].
J Hepatobiliary Pancreat Surg,
2008，
15(
1)：
63-
68.
.
[77]
MattiucciGC, AutorinoR, TringaliA, et al.
A Phase I study of high-dose-rate intraluminal brachytherapy as palliative treatment inextrahepatic biliary tract cancer[J].
Brachytherapy,
2015,
14(
3)：
401-
404.
.
[78]
胡冰，周岱云，龚彪.
可膨式金属胆道支架解除恶性胆管梗阻的临床应用及其疗效分析[J].
中华外科杂志，
1999，
37(
5)：
282-
285.
.
[79]
胡冰，周岱云，龚彪，等.
1215例次恶性胆管梗阻内镜治疗的体会[J].
中华外科杂志，
2001，
39(
3)：
195-
198.
.
[80]
SaleemA, LeggettCL, MuradMH, et al.
Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction[J].
Gastrointest Endosc,
2011，
74(
2)：
321-
327.
.
[81]
WitzigmannH, BerrF, RingelU, et al.
Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection[J].
Ann Surg,
2006,
244(
2)：
230-
239.
.
[82]
ParkDH, LeeSS, ParkSE, et al.
Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma[J].
Eur J Cancer,
2014,
50(
7)：
1259-
1268.
.
[83]
WagnerA, WiedmannM, TannapfelA, et al.
Neoadjuvant down-sizing of hilar cholangiocarcinoma with photodynamic therapy － Long-term outcome of a phase II pilot study[J].
Int J Mol Sci,
2015，
16(
11)：
26619-
26628.
.
[84]
SchmidtA, BloechingerM, WeberA, et al.
Short-term effects and adverse events of endoscopically applied radiofrequency ablation appear to be comparable with photodynamic therapy in hilar cholangiocarcinoma[J].
United European Gastroenterol J,
2016，
4(
4)：
570-
579.
.
[85]
DolakW, SchwaighoferH, HellmichB, et al.
Austrian PDT study group. Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: a nationwide retrospective study of 150 consecutive applications[J].
United European Gastroenterol J,
2017,
5(
1)：
104-
110.
.
[86]
胡贤荣，胡冰.
光动力治疗在胆管癌姑息性治疗中的应用[J].
中国微创外科杂志，
2015，
15(
5)：
460-
464.
.
[87]
牟洪超，崔书中.
持续循环腹腔热灌注化疗治疗肝胆胰恶性肿瘤的临床应用[J].
消化肿瘤杂志(电子版),
2012,
4(
4)：
223-
227.
[88]
GolseN, BakrinN, PassotG, et al.
Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results[J].
J Surg Oncol,
2012,
106(
2)：
197-
203.
.
[89]
腹腔热灌注化疗技术临床应用专家协作组.
腹腔热灌注化疗技术临床应用专家共识(2016版)[J].
中华胃肠外科杂志，
2016,
19(
2)：
121-
125.
.
_files/cscd_logo.png){kind=logo}